<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878133</url>
  </required_header>
  <id_info>
    <org_study_id>OCT - 001621</org_study_id>
    <nct_id>NCT04878133</nct_id>
  </id_info>
  <brief_title>OCT Guided vs COmplete Pci in patieNts With sT Segment Elevation myocArdial infarCtion and mulTivessel Disease</brief_title>
  <acronym>OCT-CONTACT</acronym>
  <official_title>OCT Guided vs COmplete Pci in patieNts With sT Segment Elevation myocArdial infarCtion and mulTivessel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Città della Salute e della Scienza di Torino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Città della Salute e della Scienza di Torino</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      STEMI patients with multivessel disease will be randomized to complete PCI versus PCI driven&#xD;
      by high risk criteria of plaques evaluated with OCT&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with ST segment elevation myocardial infarction (STEMI), percutaneous coronary&#xD;
      intervention (PCI) of the culprit lesion significally reduces the risk of cardiovascular&#xD;
      death. How to manage in this setting non-culprit lesion in patients with multivessel disease&#xD;
      still remain a matter of debate. Recently, the COMPLETE trial showed that complete PCI of&#xD;
      every coronary stenosis &gt; 70% (or 50-69% lesions with FFR &lt; 0.8) reduces risk of myocardial&#xD;
      infarction (MI) and unstable angina (UA) at 3 years compared with culprit-lesion PCI [1].&#xD;
      Whether this findings are related to revascularization of every obstructive lesions rather&#xD;
      than lesions with vulnerable-plaque characteristics, still remain unclear.&#xD;
&#xD;
      In high risk patients such as STEMI patients, physiopathology of coronary plaque deeply&#xD;
      differs from stable angina, mainly due to peculiar features of plaque. STEMI lesions, when&#xD;
      evaluated at autopsy or at intracoronary imaging, showed a pro-thrombotic pattern, with high&#xD;
      prevalence of thin cap fibro-atheroma, plaque rupture or thrombus, and a larger amount of&#xD;
      lipids and macrophage [2-6]. In this setting, angiography, even when combined with fractional&#xD;
      flow reserve evaluation (which can describe more accurately the functional impact of the&#xD;
      plaque), has intrinsic limitations because of lack of information about plaque&#xD;
      characteristics [7,8].&#xD;
&#xD;
      Optical coherence tomography (OCT) is the latest development in intravascular coronary&#xD;
      imaging. Similarly to intravascular ultrasound (IVUS), OCT provides cross-sectional images of&#xD;
      the vessel. However, instead of sound, OCT employs light for tissue analysis that enables&#xD;
      visualization of the coronary lesions with almost microscopic precision [9,10].&#xD;
&#xD;
      This tool can find high risk vulnerable plaque without angiographic or functional signs of&#xD;
      severity, helping from misdiagnosing and under-treating these lesions, that could benefit&#xD;
      from PCI even more than obstructive lesions without vulnerable plaque characteristics.&#xD;
&#xD;
      In an OCT substudy of the COMPLETE trial, researchers determined that half of patients had&#xD;
      obstructive nonculprit lesions with vulnerable plaque, which could explain why complete&#xD;
      revascularization conferred better outcomes than culprit lesion-only revascularization in the&#xD;
      main trial. This substudy pointed out also a 20% of non-obstructive non-culprit lesions with&#xD;
      vulnerable plaque caracteristics and up to 30% of obstructive non-culprit lesions without&#xD;
      high risk morphology [11]. It suggest that a morphological approach to PCI in high risk&#xD;
      patients can provide a more specific treatment compared with standard angiographic/functional&#xD;
      approach. A correct identification of coronary plaque instability in a setting of STEMI&#xD;
      patients could deeply impact in these patients risk of cardiovascular events, angina and re-&#xD;
      hospitalization.&#xD;
&#xD;
      Being coronary artery disease a pandemic disease with an important impact on nations health&#xD;
      care, a reduction in events in these patients do not impact only on patients quality of life,&#xD;
      but on health care system resources.&#xD;
&#xD;
      Consequently, we propose a randomized controlled trial to evaluate the effective benefit of&#xD;
      OCT guided vs complete PCI in STEMI patients with multivessels coronary artery disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with STEMI who underwent successful culprit-lesion PCI will be enrolled after the index PCI. Eligible patients will be required to have residual multivessel disease, defined as at least one stenosis &gt;&#xD;
50 %. Patients will be randomized in a 1:1 fashion to OCT guided PCI of non-culprit lesions (Group A) vs complete PCI. (Group B)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events (MACE)</measure>
    <time_frame>24 mounth after the recruitment in the study</time_frame>
    <description>Composite endopoint of all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, unplanned revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy end-points</measure>
    <time_frame>24 mounth after the recruitment in the study</time_frame>
    <description>Rate of all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, unplanned revascularization taking separately.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety end-points</measure>
    <time_frame>24 mounth after the recruitment in the study</time_frame>
    <description>Rate of Acute kidney injury (AKI) following OCT vs complete guided PCI, defined according to the Acute Kidney Injury Network criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety end-points</measure>
    <time_frame>24 mounth after the recruitment in the study</time_frame>
    <description>Rate of procedural complications following each PCI: periprocedural MI defined according to the Fourth Universal Definition of Myocardial Infarction [15], arterial access site complications, AKI</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Exsperimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>OCT - optical coherence tomography</intervention_name>
    <description>The principle by which OCT works is similar to ultrasound, although light waves close to infrared are used instead of ultrasounds.&#xD;
In practice, the light waves, emitted into the vessel through a special catheter positioned in the coronary artery, meet the surrounding structures and are partly absorbed and partly reflected by them. The reflected waves are picked up by a sensor positioned on the catheter and analyzed through software that produces images visible live on a special console.</description>
    <arm_group_label>Exsperimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with STEMI and residual non culprit CAD&#xD;
&#xD;
          2. Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refusal or inability to provide informed consent.&#xD;
&#xD;
          2. &lt; 18 years of age&#xD;
&#xD;
          3. Cardiogenic shock&#xD;
&#xD;
          4. Previous Coronary Artery Bypass Grafting (CABG&#xD;
&#xD;
          5. Indication for revascularization by CABG.&#xD;
&#xD;
          6. eGFR &lt; 30 ml/min/m2&#xD;
&#xD;
          7. ULM stenosis&#xD;
&#xD;
          8. Estimated life expectancy &lt; 3 year&#xD;
&#xD;
          9. Non culprit CTO lesion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio D'Ascenzo, MD</last_name>
      <phone>+390116335570</phone>
      <email>fabrizio.dascenzo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fabrizio D'Ascenzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mattia Peyracchia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Luigi Gonzaga, Orbassano</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Cerrato</last_name>
      <phone>347 9317104</phone>
      <email>enrico.cerrato@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Rivoli</name>
      <address>
        <city>Rivoli</city>
        <zip>10098</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgio Quadri</last_name>
      <phone>+ 393487936963</phone>
      <email>lo.savio.luca88@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio D'Ascenzo, MD</last_name>
      <phone>+390116336023</phone>
      <email>fabrizio.dascenzo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bosco</name>
      <address>
        <city>Torino</city>
        <zip>10144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Iannacone</last_name>
      <phone>+393391812226</phone>
      <email>mario.iannaccone@hotmail.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Citta della Salute</name>
      <address>
        <city>Turin</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrizio D'Ascenzo, MD</last_name>
      <phone>0116336023</phone>
      <email>fabrizio.dascenzo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Fabrizio D'Ascenzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Città della Salute e della Scienza di Torino</investigator_affiliation>
    <investigator_full_name>Fabrizio D'Ascenzo</investigator_full_name>
    <investigator_title>Cardiologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

